TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00770731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel (Temsirolimus)
Description: Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel (Temsirolimus)
Description: Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
Study: NCT01850134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Study Product
Study: NCT01913002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin 400 mg
Study: NCT00770731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hycamtin (Topotecan)
Description: Starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hycamtin (Topotecan)
Description: Starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (Bortezomib)
Description: Starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
Study: NCT01913002

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxifloxacin 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX4211 Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 Placebo
Study: NCT02161991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: aprepitant should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
Study: NCT01850134

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Study Product
Study: NCT04039737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qingpeng Ointment
Description: Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
Study: NCT03332836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12460A
Description: HM12460A is a long-acting insulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12460A
Description: HM12460A is a long-acting insulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12460A
Description: HM12460A is a long-acting insulin
Study: NCT04428957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Daily telemonitoring of heart rate (HR), blood pressure (BP), pulse oximetry (SpO2), spirometry (FVC), activity (accelerometry) and severity of cough and dyspnea
Study: NCT00674414

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Trastuzumab (Herceptin®) IV once weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Trastuzumab (Herceptin®) IV once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Oral everolimus once daily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Patients undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo surgery
Study: NCT04327726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Nebulization
Description: ultrasonic nebulization of 1 µg/kg dexmedetomidine for PDPH treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline Nebulization
Description: nebulization of 4mL 0.9% saline
Study: NCT03567746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Underwater EMR
Description: Polypectomy is performed under full water emersion avoiding the use of submucosal injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional EMR
Description: It will be performed in a 2-step procedure. First the formation of a submucosal injection underneath the polyp to create a submucosal safety cushion. Then EMR is performed with a polipectomy snare.
Study: NCT01822262

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive cholecystolithotomy with gallbladder reservation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic cholecystectomy
Study: NCT02641301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained release morphine sulfate, 30 mg
Description: A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
Study: NCT04505891

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and follow-up
Description: In patients allocated to the education and follow-up arm, education along with a a post-discharge healthcare visit from a multidisciplinary care team will be performed.
Study: NCT01262014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until disease progression, the development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient, or investigator decision.
Study: NCT02641301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained release morphine sulfate, 30 mg
Description: A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
Study: NCT04334460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BLD-2660
Description: BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.
Study: NCT01554449

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serious game reeducation
Description: It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serious game reeducation
Description: It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: functional MRI
Description: the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: functional MRI
Description: the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
Study: NCT01771796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and muscle resistance training
Description: After having been allocated randomly to one of the two groups, patients of Intervention Group are encouraged to follow a training program (aerobic and endurance muscle training) during 8 weeks.
Study: NCT00770731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (Bortezomib)
Description: Starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
Study: NCT02697318

Intervention type: DRUG
Group type: OTHER
Intervention: Timolol maleate 0.5% ophthalmic solution
Study: NCT03458130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG10
Description: TTR stabilizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG10
Description: TTR stabilizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Nonactive control
Study: NCT04062916

Intervention type: OTHER
Intervention: BSGE pelvic pain questionnaire and VAS scores
Description: Patients were evaluated using the BSGE pelvic pain questionnaire in terms of pre-operative and post-operative pain assessment in order to determine the effects of endometriosis surgery on the quality of life. The patients were asked to indicate their levels of dyspareunia, dysmenorrhea, and chronic pelvic pain on a VAS on the pelvic pain questionnaire.
Study: NCT00169650

Intervention type: OTHER
Intervention: Registry and database
Description: Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
Study: NCT01327352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi D
Description: oral administration
Study: NCT01443247

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: anti-d
Description: intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-d
Description: intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
Study: NCT01020812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Standard of Care
Study: NCT04209179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCO371
Description: PCO371 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCO371
Description: PCO371 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCO371
Description: PCO371 capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT01946737

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)
Study: NCT01020812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Standard of Care
Study: NCT01554618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Once Weekly
Description: 2 mg exenatide once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01946737

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Invasive coronary angiography (ICA)
Study: NCT03322410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified Peritoneal Equilibration test
Description: Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky~*  High : D/P creatinine\>0,8; D/D0 glucose\<0,25~*  High average : 0,65\< D/P creatinine \<0,8; 0,25\< D/D0 glucose \<0,38~*  Low average : 0,5\< D/P creatinine \<0,65; 0,39\< D/D0 glucose \< 0,48~*  Low  : D/P creatinine\<0,5 ; D/D0 glucose\>0,49.
Study: NCT02709811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Study: NCT01873040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media plus information pages
Description: Participants will receive access to the study vaccine website information pages and social media feature including blogs, discussion forums, expert chats, and ask an expert.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccine Information Pages
Description: Participants will receive access to the study vaccine website information pages.
Study: NCT03787355

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Morse connection Implants
Description: 2 neighboring morse connection Implants of Zinedent - Strauman

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Morse connection Implants
Description: 2 neighboring morse connection Implants of Zinedent - Strauman
Study: NCT00897468

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.

Intervention type: OTHER
Intervention: medical chart review
Description: patient chart review will occur in conjunction with patient data collection for final analyses.
Study: NCT05224453

Intervention type: OTHER
Group type: OTHER
Intervention: Physical training and high protein diet
Description: In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (\>1 g/kg aBW/d)

Intervention type: OTHER
Group type: OTHER
Intervention: Physical training and low protein diet
Description: In addition to the integrated physical training exercises, group B received low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (\<1 g/kg aBW/d)
Study: NCT02544919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMOF lipid (SMOFLIPID) pre treatment
Description: Experimental Arm
Study: NCT00999440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
Study: NCT02253953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D4
Study: NCT00953849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib (400 mg twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib plus Calcitriol
Description: 3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
Study: NCT03047408

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video polysomnography
Description: the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.
Study: NCT03247140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1401
Description: Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1401
Description: Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine, Rosuvastatin
Description: Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine, Rosuvastatin
Description: Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
Study: NCT01588873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel
Description: The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.~After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.~Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel
Description: The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.~After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.~Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment.
Study: NCT00250731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone support and behavior change
Description: Diabetes self-management education provided over the telephone either for individuals or couples

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telephone support and behavior change
Description: Diabetes self-management education provided over the telephone either for individuals or couples

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diabetes self-management education
Description: Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
Study: NCT02335359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid diluted in 100 ml of saline solution (loading dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid undiluted (continous infusion)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT02617602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal directed therapy
Description: Based on transpulmonary thermodilution data, the following interventions will be implemented:~Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;~cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:~* decreased heart rate (HR): dobutamine, dopamine;~* normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT02253953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D10

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT02399345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir, dasabuvir
Description: tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir (SOF)
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: tablet
Study: NCT04504682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulation
Description: Patients will be encouraged to ambulate for 20 minutes of every hour.
Study: NCT03541616

Intervention type: DEVICE
Intervention: ECG Patch, pocket ECG monitor
Description: Two consecutive 14-day ECG monitor patches or one single 28-day pocket ECG monitor (28-days total monitoring) implemented at the time of hospital discharge .
Study: NCT02253953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT01597999

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Description: magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features
Study: NCT02253953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ritonavir
Study: NCT03833063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin A
Description: glabellar injections with botulinum toxin A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: glabellar injections with sodium chloride
Study: NCT02376868

Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: OCT machines used for diagnostic purposes

Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: OCT machines used for diagnostic purposes
Study: NCT01786915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia 50mg
Study: NCT02376868

Intervention type: DEVICE
Intervention: 3D OCT-1 Maestro
Description: OCT machines used for diagnostic purposes

Intervention type: DEVICE
Intervention: iVue
Description: OCT machines used for diagnostic purposes

Intervention type: DEVICE
Intervention: iVue
Description: OCT machines used for diagnostic purposes

Intervention type: DEVICE
Intervention: iVue
Description: OCT machines used for diagnostic purposes